A small molecule glycomimetic antagonist of E-selectin (GMI-1271) prevents pancreatic tumor metastasis and offers a novel treatment for improved efficacy of chemotherapy

Summary: Pancreatic cancer (PC) has a poor prognosis, and targeting CXCR2/1 using small molecule inhibitors shows promise in inhibiting PC growth, angiogenesis, and metastasis. In this study, the therapeutic utility of the CXCR2/1 antagonist SCH-479833 was evaluated in different PC murine models, demonstrating antitumor and anti-metastatic effects. CXCR2/1 antagonist treatment inhibited tumor cell proliferation, migration, angiogenesis, and neutrophil recruitment, while promoting apoptosis, fibrosis, tumor necrosis, and extramedullary hematopoiesis. These findings suggest that selectively targeting CXCR2/1 with small molecule inhibitors is a promising therapeutic approach for PC.

Summary: This study suggests that inhibiting mitochondrial redox signaling could be a potential therapeutic option to prevent metastatic progression of pancreatic cancer. The mitochondria-targeted antioxidant, MitoQ, selectively represses the respiration of mesenchymal pancreatic cancer cells and reduces the production of harmful substances. Additionally, MitoQ inhibits cancer cell migration, invasion, and the expression of stem cell markers. Combination treatments with chemotherapy are also feasible.

Summary: The study evaluated the outcomes of metastatic pancreatic cancer patients who underwent liver metastases-directed ablative radiotherapy, finding that Eastern Cooperative Oncology Group performance status, progression of liver metastases on chemotherapy, and pre-treatment CA 19-9 levels were predictors of overall survival.